Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

maceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Pruvel(TM) (prulifloxacin) is an antibiotic which has completed two Phase 3 clinical trials for the treatment of infectious diarrhea in travelers. Additional information can be found at http://www.optimerpharma.com.

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the development of fidaxomicin and Pruvel and their potential efficacy as treatments for their intended indications, the timing and anticipated results of clinical trials and partnership discussions, and plans related to regulatory filings. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs, uncertainty regarding regulatory requirements for approval, the timing of regulatory submissions and the uncertainty regarding whether suc
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... Biosciences Corporation announced today the enrollment and dosing at ... of the first patient in the ACE ( ... Phase 2 pivotal trial in patients with relapsed or ... novel, orally available, potent and highly selective small molecule ... (FLT3) inhibitor. The ACE study is designed to ...
(Date:12/11/2009)... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ... appointment of Dr. Alan Warrander to the role ... Development. ,, "Dr. Warrander will be responsible for ... REOLYSIN(R)," said Dr. Brad Thompson, President and CEO ... design of a Phase 3 trial examining REOLYSIN ...
(Date:12/10/2009)... 10 Endologix, Inc. (Nasdaq: ELGX ... disorders, announced today that Dan Lemaitre, former President ... Board of Directors effective December 11, 2009. ... non-independent directors. ,, Franklin D. Brown, Chairman of ... Dan Lemaitre to the Endologix Board of Directors. ...
(Date:12/10/2009)... MISSISSAUGA, ON, Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences ... a life sciences product development company that identifies ... products at various stages of development, today provided ... result in the merger of Cytopia Ltd. into ... 5, 2009. The board of directors of Cytopia ...
Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Endologix Appoints Dan Lemaitre to its Board of Directors 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4
... (GPhA) President and CEO Kathleen Jaeger today,released the ... on their efforts to improve the generic drug,approval ... of increasing efficiency in the generic,approval system, another ... the,job done. What consumers need is for the ...
... N.J., Oct. 4 Vicus Therapeutics, LLC, an,oncology-focused, ... and Chief Executive Officer, will,participate in two panel ... an Industry Perspective" and "Exit Strategies:,Managing Risk and ... 2007. The,sessions will run from 9:00 a.m. to ...
... CALGARY, Oct. 4 /PRNewswire-FirstCall/ - Ms. Mary Ann Dillahunty, ... ONCY), will present a corporate overview of the Company ... p.m. PT. The conference,will be held at the Palace ... A live audio link to the webcast presentation is ...
Other Biology Technology:Statement from GPhA President and CEO Kathleen Jaeger on FDA's Generic Initiative 2Vicus Therapeutics' Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels 2Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007 2
(Date:12/14/2009)... at Rice University and Baylor College of Medicine (BCM) ... in real time with MRI as it homes in ... and kills them with heat. The all-in-one particle is ... called "theranostics" that develops technologies physicians can use to ... The research is available online in the journal ...
(Date:12/14/2009)... transmitted by sneezing, touching, or for Tasmanian devils ... that may have driven the dinosaurs to extinction through ... a member of f1000 Biology, highlights the ,paleobiological detective ... One. This led them to deduce that a protozoan ... seen in many tyrannosaurid fossils. , The parasite,s modern-day ...
(Date:12/14/2009)... you are spending the holidays with big Uncle Frank ... be better off with another family, spare a thought ... team from McMaster University and the University of New ... that lives in groups, members make strategic decisions about ... the current issue of Biology Letters . , ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2Special Ultrasound Accurately Identifies Skin Cancer 62303 1Special Ultrasound Accurately Identifies Skin Cancer 62303 2Special Ultrasound Accurately Identifies Skin Cancer 62303 3MRI Helps Detect Life Threatening Pregnancy Complication 62301 1MRI Helps Detect Life Threatening Pregnancy Complication 62301 2MRI Helps Detect Life Threatening Pregnancy Complication 62301 3HealthPlus Launches New Medicare Advantage Plans 62300 1HealthPlus Launches New Medicare Advantage Plans 62300 2HealthPlus Launches New Medicare Advantage Plans 62300 3
... Max Planck researchers in Bad Nauheim discover the mechanism ... or heart muscle tissue. ,There is disagreement, however, about ... from the Max Planck Institute for Heart and Lung ... from Martin Luther University in Halle-Wittenberg, have now shown ...
... Energy's (DOE) Office of Science has established a ... of Hurricane Katrina. , "Our colleagues in science ... Dr. Raymond L. Orbach, director of DOE's Office ... to: universities and colleges, including those in ...
... by manipulating the mosquitoes' sense of smell is the ... University, that has been selected to receive $8.5 million ... , The initiative, which was launched by the Bill ... of 43 "groundbreaking" research projects to improve health in ...
Other Biology News:Tissue regeneration operates differently than expected 2Tissue regeneration operates differently than expected 3DOE's Office of Science sets up program to aid scientists displaced by Hurricane Katrina 2Fighting malaria by manipulating mosquitoes' sense of smell 2Fighting malaria by manipulating mosquitoes' sense of smell 3
... DNA Engine Dyad thermal cycler is ... (PCR). The chassis accommodates a variety ... assemblies), which hold different types and ... graphical programming with point-and-click navigation. Peltier ...
... IHC Select Immunophosphatase Secondary Detection System is ... Select Prediluted Primary Antibody reagents, which contain ... identification of antigens by light microscopy in ... Detection System may also be used with ...
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
Biology Products: